ProQR Therapeutics (PRQR) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 2 Phase 2[2], 1 Phase 1[3].
Trial NCT03913143[5] evaluates sepofarsen in Leber Congenital Amaurosis 10 with a target enrollment of 36 participants.
No Form 4 insider filings for PRQR were recorded at the SEC in the past 30 days[6].